EBIT at other companies
Other financials
Where this comes from
Calculated from Monopar Therapeutics’s reported figures.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's EBIT?
- Monopar Therapeutics (MNPR) reported EBIT of -$5.23M in Q1 2026.
- How has Monopar Therapeutics's EBIT changed year-over-year?
- Monopar Therapeutics's EBIT decreased by 62.2% year-over-year, from -$3.22M to -$5.23M.
- What is the long-term trend for Monopar Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Monopar Therapeutics's EBIT has grown at a 16.3% compound annual growth rate (CAGR), from -$9.13M to -$16.7M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.